West Nile Virus Antibody, IgG and IgM, Spinal Fluid
Use
This test aids in the diagnosis of central nervous system infection with West Nile virus by detecting the presence of IgM and IgG-class antibodies in spinal fluid. It is especially useful in patients with suspected mosquito-borne meningitis or encephalitis. The presence of specific IgM-class antibodies is consistent with the acute phase of meningitis or encephalitis caused by West Nile virus, while IgG-class antibodies may indicate recent or past central nervous system infection.
Special Instructions
Not provided.
Limitations
The test results should be interpreted with caution and used in conjunction with clinical evaluation and other diagnostic procedures. The significance of negative results in immunosuppressed patients is uncertain, and false-positive results may occur due to cross-reactivity with other flaviviruses. The assay cannot distinguish between intrathecal antibody synthesis and serum antibodies introduced into CSF.
New York Approved
Methodology
Immunoassay (ELISA)
Biomarkers
West Nile Virus Antibody IgG
AntibodyWest Nile Virus Antibody IgM
Antibody
LOINC Codes
- 94853-9 - WNV IgG+IgM Pnl CSF
- 77953-8 - WNV IgG CSF Ql IA
- 29569-1 - WNV IgM CSF Ql IA
- 69048-7 - Immunologist review
Result Turnaround Time
1-4 days
Related Documents
For more information, please review the documents below
Specimen
Cerebrospinal Fluid
Volume
1 mL
Minimum Volume
0.8 mL
Container
Plastic vial
Collection Instructions
Submit specimen from collection vial 2, 3, or 4.
Causes for Rejection
Gross hemolysis
Stability Requirements
| Temperature | Period |
|---|---|
| Refrigerated | 7 days |
| Frozen | 30 days |